BRIEFLY

Stockwatch Daily - - HEALTH CARE -

- Abat­tis Bio­ceu­ti­cals Corp. has started sell­ing its VB-1, VB-2, CA-2 and the KB-1 va­por­iz­ers on its web­site. (ATT) $0.17

- Acasti Pharma Inc. has closed a $19.1-mil­lion (U.S.) pub­lic of­fer­ing con­sist­ing of 16.6 mil­lion shares at $1 (U.S.) each. (ACST) $1.49

- Arev Brands In­ter­na­tional Ltd. has ap­pointed Mike Withrow as CEO fol­low­ing the res­ig­na­tion of Stephane Ma­her, ef­fec­tive Oct. 11, 2018. Mr. Ma­her will re­main with the com­pany as the busi­ness de­vel­op­ment man­ager of Que­bec. (AREV) $0.38

- Avi­vagen Inc. has signed its first dis­tri­bu­tion agree­ment for OxC-beta live­stock in Malaysia. (VIV) $0.54

- Bausch Health Com­pa­nies Inc. and its der­ma­tol­ogy busi­ness, Ortho Der­ma­to­log­ics, have noted the jour­nal pub­li­ca­tion of phase 3 re­sults ex­am­in­ing the safety and ef­fec­tive­ness of Al­treno lo­tion. (BHC) $31.78

- East­wood Bio-Med­i­cal Canada Inc. is seek­ing man­u­fac­tur­ing clients with sev­eral health food com­pa­nies. (EBM) $6.40

- MedX Health Corp. has closed a $337,000 first tranche of its pri­vate place­ment. It has is­sued 2.1 mil­lion units at 16 cents each. (MDX) $0.16

- Nat­u­rally Splen­did En­ter­prises Ltd. and Neu­triSci In­ter­na­tional Inc. have ex­tended and added bind­ing terms to their LOI. The par­ties hope to sign a de­fin­i­tive agree­ment soon, which will in­clude at least two Neu­triSci-for­mu­lated sub­lin­gual tablets. (NSP) $0.24, (NU) $0.21

- Ny­mox Phar­ma­ceu­ti­cal Corp. is on track with its reg­u­la­tory fil­ings for fexapotide tri­flu­tate. The com­pany has al­tered its in­ter­nal qual­ity con­trol ac­tiv­i­ties by ex­pand­ing its team and open­ing a new of­fice in Or­ange County, Cal­i­for­nia. (NYMX) $0.00

- On­colyt­ics Biotech Inc. has pub­lished an ab­stract on pelare­o­rep for the Euro­pean So­ci­ety for Med­i­cal On­col­ogy 2018 Congress. (ONC) $4.43

- Pe­di­apharm Inc. has been halted at 6:22 a.m. PT on Oct. 11, 2018, at the com­pany’s re­quest, pend­ing news. (PDP) $0.31

- Pe­di­apharm Inc. has closed a $62-mil­lion of­fer­ing of sub­scrip­tion re­ceipts. (PDP) $0.31

- Pe­di­apharm Inc. will re­sume at 9:45 a.m. PT on Oct. 11, 2018. (PDP) $0.31

- Pre­ferred Den­tal Tech­nolo­gies Inc. and Logic Den­tal So­lu­tions have part­nered to de­velop den­tal demon­stra­tion mod­els. (PDTI) $0.05

- Promis Neu­ro­sciences Inc. has iden­ti­fied po­ten­tial an­ti­body ther­a­peu­tic can­di­dates aimed at tar­get­ing toxic oligomers of the pro­tein a-synu­clein. This is con­sid­ered a root cause of Parkin­son’s disease. (PMN) $0.29

- Rele­vium Tech­nolo­gies Inc. plans to in­crease its Bio­ganix of­fer­ing on the Wal­mart web­site. It hopes to add up to 30 new SKUs of its Bio­ganix Gold Se­ries for­mu­lated prod­ucts by year-end. (RLV) $0.14

- RepliCel Life Sciences Inc.’s share­holder, YOFOTO (China) Health, has com­pleted its in­vest­ment. It pur­chased 5.35 mil­lion shares and 1.07 mil­lion war­rants for $5.09-mil­lion. (RP) $0.43

- Scythian Bio­sciences Corp. tar­get Can­nCure In­vest­ments Inc. has re­ceived ap­proval for the trans­fer of 60 per cent of the eq­uity of 3 Boys Farms LLC to Can­nCure. The trans­fer will in­clude 3 Boys Farms’ med­i­cal mar­i­juana treat­ment cen­tre li­cence in Flor­ida. (SCYB) $4.39

- Sona Nan­otech Inc. will sup­ply its gold nanorods to Ex­pe­deon Ltd., a global biotech com­pany. Ex­pe­deon will have the rights to pro­mote and mar­ket the nanorods to life sci­ence re­searchers and di­ag­nos­tic com­pa­nies glob­ally. (SONA) $0.26

- Sweet Nat­u­ral Trad­ing Co. Ltd. has closed the first tranche of its pri­vate place­ment, is­su­ing 12.14 mil­lion units for $607,000. The com­pany will use the pro­ceeds for gen­eral work­ing cap­i­tal. (NTRL) $0.05

- Therma Bright Inc. has hired a re­search group to fur­ther its test­ing on the TherOZap tech­nol­ogy against the Zika virus. The com­pany says it has made im­prove­ments to the TherOZap tech­nol­ogy com­pared with the pre­vi­ous ver­sion. (THRM) $0.03

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.